强直性脊柱炎（AS）是一种具有挑战性的疾病，其特征是慢性炎症和结构损伤，主要影响中轴骨骼，同时也可能出现关节外表现。这导致患者的生活质量恶化。在过去的几十年里，肿瘤坏死因子-α (TNF-α) 抑制剂彻底改变了 AS 的治疗，显着缓解症状并改善患者预后。本综述的目的是评估 TNF-α 抑制剂对活动性 AS 患者的疗效。使用以下关键词在 PubMed 数据库中进行搜索：（“TNF α 抑制剂”OR“抗 TNF-a”OR“TNF-a 抑制剂”OR“抗 TNF-α”OR“依那西普”OR“戈利木单抗”OR“英夫利昔单抗”或“聚乙二醇赛妥珠单抗”或“阿达木单抗”）和“强直性脊柱炎”。检索于 2024 年 2 月完成，根据 PRISMA 指南，本次综述纳入了 35 项研究。研究结果揭示了支持 TNF-α 抑制剂在减少炎症、预防结构损伤和增强 AS 患者整体健康方面功效的证据。总体而言，TNF-α 抑制剂已成为 AS 治疗算法的基石，具有非常令人满意的安全性。版权所有 © 2024，Zouris 等人。

Ankylosing spondylitis (AS) is a challenging disease, characterized by chronic inflammation and structural damage primarily affecting the axial skeleton, while extra-articular manifestations may also appear. This results in the deterioration of patients' quality of life. Over the past few decades, tumor necrosis factor-α (TNF-α) inhibitors have revolutionized the management of AS, offering substantial relief from symptoms and improving patient outcomes. The aim of this review is to assess the efficacy of TNF-α inhibitors in patients with active AS. A search was performed in the PubMed database using the following keywords: ("TNF alpha inhibitors" OR "anti TNF-a" OR "TNF-a inhibitors" OR "anti TNF-alpha" OR "Etanercept " OR "Golimumab" OR "Infliximab" OR "Certolizumab pegol" OR "Adalimumab") AND "ankylosing spondylitis". The search was completed in February 2024, and 35 studies were included in this review following PRISMA guidelines. The findings reveal evidence supporting the efficacy of TNF-α inhibitors in reducing inflammation, preventing structural damage, and enhancing overall well-being in AS patients. Overall, TNF-α inhibitors have emerged as a cornerstone in the therapeutic algorithm against AS with a very satisfactory safety profile.Copyright © 2024, Zouris et al.